Esketamine for Depressed Adolescents at Imminent Suicide Risk
April 7, 2026
Adolescents with depression have approximately a fivefold increased...
Read More
Clozapine After Failed Drug Trial in First-Episode Psychosis
April 6, 2026
Antipsychotic treatment algorithms in first-episode psychosis (FEP)...
Read More
From Awareness to Action: World Bipolar Day
March 30, 2026
World Bipolar Day is celebrated each year on March 30th. World Bipo...
Read More
FDA Expands Flibanserin Approval to Postmenopausal Women With Hypoactive Sexual Desire Disorder
March 24, 2026
The FDA has recently granted expanded approval for flibanserin to t...
Read More
Exercise Demonstrates Moderate Effects for Depression and Anxiety Across the Lifespan
March 19, 2026
A recent meta-meta-analysis examining the effects of structured exe...
Read More
Rethinking Mood Disorder Treatment with Immunometabolic Insights
March 17, 2026
While there are many stimulant and non-stimulant options targeting ...
Read More
Brain Awareness Week: March 16-22, 2026
March 16, 2026
Each March, the global community comes together to celebrate Brain ...
Read More
FDA Accepts New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension
March 9, 2026
In February 2026, Teva Pharmaceuticals announced that the FDA has a...
Read More
Ketogenic Diet Shows Modest Short-Term Benefit in Treatment-Resistant Depression
March 5, 2026
Studies have suggested that a ketogenic diet –a high-fat, low-carbo...
Read More
Long-Term Impact of Cognitive Training on Dementia Risk: 20-Year Outcomes From a Randomized Trial
March 2, 2026
In older adults, cognitive training can facilitate long-term improv...
Read More
Preinjury Antidepressant Use Does Not Appear to Worsen Clinical Outcomes after TBI
February 26, 2026
Concerns have long circulated that serotonergic antidepressants may...
Read More
FDA Approves Milsaperidone for Schizophrenia and Acute Bipolar I Disorder
February 20, 2026
The FDA has approved milsaperidone for the treatment of schizophren...
Read More